These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38619037)

  • 1. Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS.
    Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M
    Mult Scler; 2024 Jun; 30(7):833-842. PubMed ID: 38619037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial.
    Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Skripchenko N; Cui LY; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M;
    Lancet Neurol; 2021 Dec; 20(12):1001-1011. PubMed ID: 34800398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial.
    Kuhle J; Chitnis T; Banwell B; Tardieu M; Arnold DL; Rawlings AM; Geertsen SS; Lublin AL; Saubadu S; Truffinet P; Kappos L
    Mult Scler; 2023 Mar; 29(3):385-394. PubMed ID: 36632983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW;
    Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
    Kappos L; Fox RJ; Burcklen M; Freedman MS; Havrdová EK; Hennessy B; Hohlfeld R; Lublin F; Montalban X; Pozzilli C; Scherz T; D'Ambrosio D; Linscheid P; Vaclavkova A; Pirozek-Lawniczek M; Kracker H; Sprenger T
    JAMA Neurol; 2021 May; 78(5):558-567. PubMed ID: 33779698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Ponesimod Compared with Teriflunomide in Female Patients with Relapsing Multiple Sclerosis: Findings from the Pivotal OPTIMUM Study.
    Jones RR; Turkoz I; Ait-Tihyaty M; DiBernardo A; Houtchens MK; Havrdová EK
    J Womens Health (Larchmt); 2024 Apr; 33(4):480-490. PubMed ID: 38301149
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and Safety of Teriflunomide in Chinese Patients with Relapsing Forms of Multiple Sclerosis: A Subgroup Analysis of the Phase 3 TOWER Study.
    Qiu W; Huang DH; Hou SF; Zhang MN; Jin T; Dong HQ; Peng H; Zhang CD; Zhao G; Huang YN; Zhou D; Wu WP; Wang BJ; Li JM; Zhang XH; Cheng Y; Li HF; Li L; Lu CZ; Zhang X; Bu BT; Dong WL; Fan DS; Hu XQ; Xu XH;
    Chin Med J (Engl); 2018 Dec; 131(23):2776-2784. PubMed ID: 30511679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ofatumumab versus Teriflunomide in Multiple Sclerosis.
    Hauser SL; Bar-Or A; Cohen JA; Comi G; Correale J; Coyle PK; Cross AH; de Seze J; Leppert D; Montalban X; Selmaj K; Wiendl H; Kerloeguen C; Willi R; Li B; Kakarieka A; Tomic D; Goodyear A; Pingili R; Häring DA; Ramanathan K; Merschhemke M; Kappos L;
    N Engl J Med; 2020 Aug; 383(6):546-557. PubMed ID: 32757523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
    Montalban X; Vermersch P; Arnold DL; Bar-Or A; Cree BAC; Cross AH; Kubala Havrdova E; Kappos L; Stuve O; Wiendl H; Wolinsky JS; Dahlke F; Le Bolay C; Shen Loo L; Gopalakrishnan S; Hyvert Y; Javor A; Guehring H; Tenenbaum N; Tomic D;
    Lancet Neurol; 2024 Nov; 23(11):1119-1132. PubMed ID: 39307151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
    Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS].
    Boyko AN; Alifirova VM; Lukashevich IG; Goncharova ZA; Greshnova IV; Zaslavsky LG; Kotov SV; Malkova NA; Mishin GN; Parshina EV; Poverennova IY; Prakhova LN; Sivertseva SA; Smagina IV; Totolyan NA; Trinitatsky YV; Trushnikova TN; Khabirov FA; Chefranova JY; Shchur SG; Dudin VA; Pokhabov DV; Artemeva AV; Eremeeva AV; Linkova YN; Zinkina-Orikhan AV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(4):86-96. PubMed ID: 38676683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
    Steinman L; Fox E; Hartung HP; Alvarez E; Qian P; Wray S; Robertson D; Huang D; Selmaj K; Wynn D; Cutter G; Mok K; Hsu Y; Xu Y; Weiss MS; Bosco JA; Power SA; Lee L; Miskin HP; Cree BAC;
    N Engl J Med; 2022 Aug; 387(8):704-714. PubMed ID: 36001711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial.
    Freedman MS; Wolinsky JS; Wamil B; Confavreux C; Comi G; Kappos L; Olsson TP; Miller A; Benzerdjeb H; Li H; Simonson C; O'Connor PW;
    Neurology; 2012 Jun; 78(23):1877-85. PubMed ID: 22622860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.
    Miller AE
    Clin Ther; 2015 Oct; 37(10):2366-80. PubMed ID: 26365096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.
    Comi G; Freedman MS; Kappos L; Olsson TP; Miller AE; Wolinsky JS; O'Connor PW; Benamor M; Dukovic D; Truffinet P; Leist TP
    Mult Scler Relat Disord; 2016 Jan; 5():97-104. PubMed ID: 26856952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
    O'Connor P; Comi G; Freedman MS; Miller AE; Kappos L; Bouchard JP; Lebrun-Frenay C; Mares J; Benamor M; Thangavelu K; Liang J; Truffinet P; Lawson VJ; Wolinsky JS;
    Neurology; 2016 Mar; 86(10):920-30. PubMed ID: 26865517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study.
    Miller AE; Olsson TP; Wolinsky JS; Comi G; Kappos L; Hu X; Xu X; Lublin AL; Truffinet P; Chavin J; Delhay JL; Benamor M; Purvis A; Freedman MS;
    Mult Scler Relat Disord; 2020 Nov; 46():102438. PubMed ID: 32911306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.
    Miller AE; O'Connor P; Wolinsky JS; Confavreux C; Kappos L; Olsson TP; Truffinet P; Wang L; D'Castro L; Comi G; Freedman MS;
    Mult Scler; 2012 Nov; 18(11):1625-32. PubMed ID: 22723573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.